Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary form of immunotherapy that has shown significant promise in treating various types of cancer, particularly hematologic malignancies such as leukemia and lymphoma. This therapy involves genetically engineering a patient's T-cells to express receptors specifically targeting and destroying cancer cells.
According to BCC Research, the global market for CAR T-cell therapy is expected to increase significantly. In 2024, it was valued at approximately $4.6 billion and is projected to reach $25.1 billion by the end of 2029, growing at a compound annual growth rate (CAGR) of 40.2%. This impressive growth is driven by several factors, including the increasing incidence of cancer, the Growing significance of precision medicine, and Growing investments and funding in CAR T-cell therapy research.